Anti-Phospholipase A(2) Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy

Rituximab induces nephrotic syndrome (NS) remission in two-thirds of patients with primary membranous nephropathy (MN), even after other treatments have failed. To assess the relationships among treatment effect, circulating nephritogenic anti-phospholipase A(2) receptor (anti-PLA(2)R) autoantibodie...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Am Soc Nephrol
Auteurs principaux: Ruggenenti, Piero, Debiec, Hanna, Ruggiero, Barbara, Chianca, Antonietta, Pellé, Timothee, Gaspari, Flavio, Suardi, Flavio, Gagliardini, Elena, Orisio, Silvia, Benigni, Ariela, Ronco, Pierre, Remuzzi, Giuseppe
Format: Artigo
Langue:Inglês
Publié: American Society of Nephrology 2015
Sujets:
Clinical Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4587688/
https://ncbi.nlm.nih.gov/pubmed/25804280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2014070640
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires